



Approved for use through 04/30/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Application Number	10/586,892
Filing Date	February 9, 2007
First Named Inventor	David S. Lawrence
Art Unit	1636
Examiner Name	Jennifer Ann Dunston
Attorney Docket Number	96700/1160

[illegible][illegible]Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JD/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/586,892		
		Filing Date	February 9, 2007		
		First Named Inventor	David S. Lawrence		
		Art Unit	1636		
Examiner Name	Jennifer Ann Dunston				
Sheet	2	of	4	Attorney Docket Number	96700/1160

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	ANDREASSI C et al., entitled "Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients," Human Molecular Genetics, 2001, Vol. 10, No. 24, 2841-2849.	
	5	BURATTI E et al., entitled "Can a 'patch' in a skipped exon make the pre-mRNA splicing machine run better?" Trends in Molecular Medicine, Vol. 9, No. 6, June 2003, 229-232.	
	6	CARTEGNI L et al., entitled "Correction of disease-associated exon skipping by synthetic exon-specific activators," Nature Structural Biology, Vol. 10, No. 2, February 2003, 120-125.	
	7	CHANG J G, et al., entitled "Treatment of spinal muscular atrophy by sodium butyrate," PNAS, August 14, 2001, Vol. 98, No. 17, 9808-9813.	
	8	CLANCY J P et al., entitled "Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis," Am J Respir Crit Care Med, Vol 163, 1683-1692, 2001.	
	9	KAUFMAN R J, entitled "Correction of genetic disease by making sense from nonsense," The Journal of Clinical Investigation, August 1999, Vol. 104, No. 4, 367-368.	
	10	KHOO B et al., entitled Putting some spine into alternative splicing," Trends in Biotechnology, Vol. 21, No. 8, August 2003, 328-330.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JD/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/586,892		
		Filing Date	February 9, 2007		
		First Named Inventor	David S. Lawrence		
		Art Unit	1636		
Examiner Name	Jennifer Ann Dunston				
Sheet	3	of	4	Attorney Docket Number	96700/1160

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	LUKACS G L et al., entitled "Pharmacologic Approaches to Correcting the Basic Defect in Cystic Fibrosis," N Engl J Med 349;15, 1401-1404, October 9, 2003.	
	12	MANKIN A S et al., entitled "Baby, don't stop!" Nature Genetics, Vol. 23, September 1999, 8-10.	
	13	POLITANO L et al., entitled "Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results," Acta Myol, 2003, May;22(1):15-21, Abstract Only.	
	14	SKORDIS L A et al., entitled "Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts,"	
		PNAS, April 1, 2003, Vol. 100, No. 7, 4114-4119.	
	15	WILSCHANSKI M et al., entitled "A Pilot Study of the Effect of Gentamicin on Nasal Potential Difference Measurements in Cystic Fibrosis Patients Carrying Stop Mutations,"	
		Am J Respir Crit Care Med, Vol. 161, 860-865, 2000.	
	16	WILSCHANSKI M et al., entitled "Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations,"	
		N Engl J Med 349;15, October 9, 2003, 1433-1441.	
	17	XI B et al., entitled "Enhanced Production of Functional Proteins from Defective Genes," J. Am. Chem. Soc., 2004, 126, 5660-5661 & Supporting Info. S1-S12	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JD/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/586,892		
		Filing Date	February 9, 2007		
		First Named Inventor	David S. Lawrence		
		Art Unit	1636		
		Examiner Name	Jennifer Ann Dunston		
Sheet	4	of	4	Attorney Docket Number	96700/1160

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	18	"PCT NOTIFICATION CONCERNING TRANSMITTAL OF COPY OF INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY," Issued by	
		The International Bureau of WIPO on September 21, 2006 in connection with International Patent Application No. PCT/US2005/007365, 6 pages.	

Examiner Signature	/Jennifer Dunston/ (12/11/2009)	Date Considered	
--------------------	---------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JD/